Literature DB >> 28329323

Duration of antiplatelet therapy after DES implantation: can we trust non-inferiority open-label trials?

Philippe Gabriel Steg1,2,3,4,5, Tabassome Simon1,3,6,7.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 28329323     DOI: 10.1093/eurheartj/ehx110

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  2 in total

1.  Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial.

Authors:  Gregory Ducrocq; Jose R Gonzalez-Juanatey; Etienne Puymirat; Gilles Lemesle; Marine Cachanado; Isabelle Durand-Zaleski; Joan Albert Arnaiz; Manuel Martínez-Sellés; Johanne Silvain; Albert Ariza-Solé; Emile Ferrari; Gonzalo Calvo; Nicolas Danchin; Cristina Avendaño-Solá; Jerome Frenkiel; Alexandra Rousseau; Eric Vicaut; Tabassome Simon; Philippe Gabriel Steg
Journal:  JAMA       Date:  2021-02-09       Impact factor: 56.272

2.  Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: A systematic review and meta-analysis.

Authors:  Nino Mihatov; Eric A Secemsky; Dean J Kereiakes; Gabriel Steg; Patrick W Serruys; Ply Chichareon; Changyu Shen; Robert W Yeh
Journal:  Catheter Cardiovasc Interv       Date:  2020-10-28       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.